Santen Pharmaceutical Co (JP:4536) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Santen Pharmaceutical Co. has successfully repurchased 3,729,200 common shares totaling over 6.29 billion yen as part of its share buyback program implemented in November 2024. The buyback is a strategic move to enhance shareholder value, with a maximum target of 5 million shares and a budget of 10 billion yen set by the company.
For further insights into JP:4536 stock, check out TipRanks’ Stock Analysis page.